965 related articles for article (PubMed ID: 26218502)
1. No changes in N-terminal pro-brain natriuretic peptide in a longitudinal cohort of patients with systemic sclerosis-associated pulmonary arterial hypertension on therapy with bosentan.
Rotondo C; Praino E; Nivuori M; di Serio F; Lapadula G; Iannone F
Int J Rheum Dis; 2017 Jan; 20(1):90-96. PubMed ID: 26218502
[TBL] [Abstract][Full Text] [Related]
2. Comparison of brain natriuretic peptide (BNP) and NT-proBNP in screening for pulmonary arterial hypertension in patients with systemic sclerosis.
Cavagna L; Caporali R; Klersy C; Ghio S; Albertini R; Scelsi L; Moratti R; Bonino C; Montecucco C
J Rheumatol; 2010 Oct; 37(10):2064-70. PubMed ID: 20634241
[TBL] [Abstract][Full Text] [Related]
3. Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry.
Chung L; Fairchild RM; Furst DE; Li S; Alkassab F; Bolster MB; Csuka ME; Derk CT; Domsic RT; Fischer A; Frech TM; Gomberg-Maitland M; Gordon JK; Hinchcliff M; Hsu V; Hummers LK; Khanna D; Medsger TAJ; Molitor JA; Preston IR; Schiopu E; Shapiro L; Hant F; Silver R; Simms R; Varga J; Steen VD; Zamanian RT
Clin Exp Rheumatol; 2017; 35 Suppl 106(4):106-113. PubMed ID: 27908301
[TBL] [Abstract][Full Text] [Related]
4. N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study.
Thakkar V; Stevens WM; Prior D; Moore OA; Byron J; Liew D; Patterson K; Hissaria P; Roddy J; Zochling J; Sahhar J; Nash P; Tymms K; Celermajer D; Gabbay E; Youssef P; Proudman SM; Nikpour M
Arthritis Res Ther; 2012 Jun; 14(3):R143. PubMed ID: 22691291
[TBL] [Abstract][Full Text] [Related]
5. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis.
Allanore Y; Borderie D; Avouac J; Zerkak D; Meune C; Hachulla E; Mouthon L; Guillevin L; Meyer O; Ekindjian OG; Weber S; Kahan A
Arthritis Rheum; 2008 Jan; 58(1):284-91. PubMed ID: 18163505
[TBL] [Abstract][Full Text] [Related]
6. Venous endotelin-1 (ET-1) and brain natriuretic peptide (BNP) plasma levels during 6-month bosentan treatment for pulmonary arterial hypertension.
Vizza CD; Letizia C; Petramala L; Badagliacca R; Poscia R; Zepponi E; Crescenzi E; Nona A; Benedetti G; Ferrante F; Sciomer S; Fedele F
Regul Pept; 2008 Nov; 151(1-3):48-53. PubMed ID: 18796317
[TBL] [Abstract][Full Text] [Related]
7. N-terminal pro-BNP in sclerodermic patients on bosentan therapy for PAH.
Simeoni S; Lippi G; Puccetti A; Montagnana M; Tinazzi E; Prati D; Corrocher R; Lunardi C
Rheumatol Int; 2008 May; 28(7):657-60. PubMed ID: 18092166
[TBL] [Abstract][Full Text] [Related]
8. Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension.
Mathai SC; Bueso M; Hummers LK; Boyce D; Lechtzin N; Le Pavec J; Campo A; Champion HC; Housten T; Forfia PR; Zaiman AL; Wigley FM; Girgis RE; Hassoun PM
Eur Respir J; 2010 Jan; 35(1):95-104. PubMed ID: 19643943
[TBL] [Abstract][Full Text] [Related]
9. N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers.
Allanore Y; Borderie D; Meune C; Cabanes L; Weber S; Ekindjian OG; Kahan A
Arthritis Rheum; 2003 Dec; 48(12):3503-8. PubMed ID: 14674001
[TBL] [Abstract][Full Text] [Related]
10. The role of asymmetric dimethylarginine alone and in combination with N-terminal pro-B-type natriuretic peptide as a screening biomarker for systemic sclerosis-related pulmonary arterial hypertension: a case control study.
Thakkar V; Stevens W; Prior D; Rabusa C; Sahhar J; Walker JG; Roddy J; Lester S; Rischmueller M; Zochling J; Nash P; Gabbay E; Youssef P; Proudman SM; Nikpour M
Clin Exp Rheumatol; 2016; 34 Suppl 100(5):129-136. PubMed ID: 27214686
[TBL] [Abstract][Full Text] [Related]
11. The clinical significance of serum N-terminal pro-brain natriuretic peptide in systemic sclerosis patients.
Choi HJ; Shin YK; Lee HJ; Kee JY; Shin DW; Lee EY; Lee YJ; Lee EB; Song YW
Clin Rheumatol; 2008 Apr; 27(4):437-42. PubMed ID: 17899307
[TBL] [Abstract][Full Text] [Related]
12. Neurohormonal activation in patients with systemic sclerosis-related pulmonary arterial hypertension.
Dimitroulas T; Giannakoulas G; Karvounis H; Sfetsios T; Koliakos G; Parcharidis G; Settas L
Int J Cardiol; 2007 Sep; 121(1):135-7. PubMed ID: 17088004
[TBL] [Abstract][Full Text] [Related]
13. Left heart disease: a frequent cause of early pulmonary hypertension in systemic sclerosis, unrelated to elevated NT-proBNP levels or overt cardiac fibrosis but associated with increased levels of MR-proANP and MR-proADM: retrospective analysis of a French Canadian cohort.
Miller L; Chartrand S; Koenig M; Goulet JR; Rich É; Chin AS; Chartrand-Lefebvre C; Abrahamowicz M; Senécal JL; Grodzicky T
Scand J Rheumatol; 2014; 43(4):314-23. PubMed ID: 25089008
[TBL] [Abstract][Full Text] [Related]
14. Non-invasive diagnostic and functional evaluation of cardiac involvement in patients with systemic sclerosis.
Ciurzyński M; Bienias P; Lichodziejewska B; Kurnicka K; Szewczyk A; Glińska-Wielochowska M; Kurzyna M; Błaszczyk M; Liszewska-Pfejfer D; Pruszczyk P
Clin Rheumatol; 2008 Aug; 27(8):991-7. PubMed ID: 18256871
[TBL] [Abstract][Full Text] [Related]
15. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension.
Williams MH; Handler CE; Akram R; Smith CJ; Das C; Smee J; Nair D; Denton CP; Black CM; Coghlan JG
Eur Heart J; 2006 Jun; 27(12):1485-94. PubMed ID: 16682379
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Macitentan in Patients With Eisenmenger Syndrome.
Gatzoulis MA; Landzberg M; Beghetti M; Berger RM; Efficace M; Gesang S; He J; Papadakis K; Pulido T; Galiè N;
Circulation; 2019 Jan; 139(1):51-63. PubMed ID: 30586694
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.
Launay D; Sitbon O; Le Pavec J; Savale L; Tchérakian C; Yaïci A; Achouh L; Parent F; Jais X; Simonneau G; Humbert M
Rheumatology (Oxford); 2010 Mar; 49(3):490-500. PubMed ID: 20015974
[TBL] [Abstract][Full Text] [Related]
18. N-terminal probrain natriuretic peptide as a biochemical marker in the evaluation of bosentan treatment in systemic-sclerosis-related pulmonary arterial hypertension.
Dimitroulas T; Giannakoulas G; Karvounis H; Koliakos G; Sfetsios T; Dimitroula H; Settas L
Clin Rheumatol; 2008 May; 27(5):655-8. PubMed ID: 18204995
[TBL] [Abstract][Full Text] [Related]
19. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
McLaughlin VV; Benza RL; Rubin LJ; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubenfire M; Seeger W
J Am Coll Cardiol; 2010 May; 55(18):1915-22. PubMed ID: 20430262
[TBL] [Abstract][Full Text] [Related]
20. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension.
Fijalkowska A; Kurzyna M; Torbicki A; Szewczyk G; Florczyk M; Pruszczyk P; Szturmowicz M
Chest; 2006 May; 129(5):1313-21. PubMed ID: 16685024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
